Canaccord Genuity Maintains Their Buy Rating on Natera (NTRA)


Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Natera (NTRA) today and set a price target of $27. The company’s shares closed yesterday at $19.95.

Massaro noted:

“We have modeled, and continue to model zero revenue for this assay; however, the draft LCD in our minds increases the probability that NTRA launches this test with Medicare reimbursement; we believe that prior to yesterday, investor and analyst expectations were kept very low, rendering this as a “show-me” launch. Even after trading +10% yesterday on this news, NTRA trades at just 3.4x our 2020 rev. estimate of $338M, which in our opinion is a material disconnect between its current valuation and what the business is actually worth. We raise our PT to $27, and should we get positive news out of ACOG (at or before the ACOG 3-6), we think the stock could hit an all-time high and gap above our raised price target. NTRA is at the top of our list of top picks for 2019; we are buyers.”

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 16.8% and a 59.5% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.

Currently, the analyst consensus on Natera is a Strong Buy with an average price target of $23.75.

See today’s analyst top recommended stocks >>

Based on Natera’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $31.84 million. In comparison, last year the company had a GAAP net loss of $45.5 million.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts